Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADDIT-GLIO: Adjuvant DC Immunotherapy + Temozolomide in Newly Diagnosed Glioblastoma
NCT02649582Phase 2Active, not recruiting
- Start
- Dec 2015
- Primary completion
- Jul 2027
- Modality
- Whole Cell Cancer Vaccines, Dendritic Cell Vaccines, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of WT1 mRNA-loaded autologous monocyte-derived dendritic cells in glioblastoma (GBM). Started Dec 2015; status: active, not recruiting.
02
Drugs
WT1 mRNA-loaded autologous monocyte-derived dendritic cells
03
Conditions
glioblastoma (GBM)
Beyond the preview
Go deeper on NCT02649582.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02649582.